In addition, most PC patients initially respond to androgen deprivation therapy (ADT, usually with the androgen synthesis inhibitor abiraterone acetate or the androgen receptor antagonist such as enzalutamide) before hormone-sensitive PC (HSPC) progresses to castration-resistance PC (CRPC) [16]. Here, AR is linked to pachyonychia congenita.